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Abstract: Background: Deletion in liver cancer gene (DLC1) and phosphorylated focal 
adhesion kinase (p-FAK) have recently been reported as metastasis-related genes. 
However, the roles and prognostic values of their expression in epithelial ovarian 
carcinomas (EOCs) remain unclear. Methods: The expression and prognostic value of 
DLC1 and p-FAK Y397 in EOC were evaluated by immunohistochemistry and multivariate 
analysis. Results: Low expression of DLC1 and high expression of p-FAK Y397  were 
found in the 76 cases of EOC. The expression of DLC1 and p-FAK Y397 were negatively 
correlated. Multivariate analysis showed that the combination of them was an independent 
prognostic marker of EOC (P = 0.0319). Conclusions: DLC1 and pFAK Y397 had an 
association with the clinicopathologic characteristics of EOC. Expression of neither of 
these genes was a prognostic factor alone, but the combination revealed a significant 
prognostic value in the 60 cases of advanced stage EOC. 
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1. Introduction 
Ovarian carcinoma is the most lethal gynecological cancer in many countries [1]. Epithelial ovarian 
carcinomas (EOC) account for approximately 70% of all ovarian malignant diseases. Due to its 
insidious localization in the pelvis, almost 70% of EOC are found at an advanced stage (stage III/IV) [2]. 
The 5-year overall survival rate of patients with advanced stage cases is no more than 20%, compared 
to 90% for early stage cases (stage I/II) [3]. Although about 65–70% of the patients initially respond to 
the conventional treatment of cytoreduction, followed by a standard first-line chemotherapy regimen 
including combined platinum-paclitaxel, more than half of these patients relapse within a short   
period [4–6]. Because of the complex mechanism underlying the recurrence of ovarian carcinoma, 
many clinical indices such as FIGO stage, tumor type and the size of residual focus, do not always 
indicate a precise prognosis
 [4]. Therefore, developing a precise prognostic index would help us to not 
only understand the bona fide mechanism underlying EOC recurrence but also to construct a set of 
effective screening methods for the relapse of EOC [7]. Progress made toward increasing the survival 
rate of advanced stage EOC will improve the total survival rate of EOC. 
Metastasis-related genes directly contribute to metastasis and recurrence, two factors that strongly 
influence the prognosis of cancer. The deletion in liver cancer gene (DLC1) is a tumor suppressor gene 
that was first identified by its deletion in a primary hepatocellular carcinoma sample [8] and subsequently 
found to be deleted or under-expressed in other cancers [9–13]. DLC1 is a GTPase-activating protein 
(GAP), and its deletion and resulting lack of interaction with a variety of downstream mediators causes 
tumorigenesis as well as uncontrolled cell growth [14,15]. Recently, abnormal, low, or lack of DLC1 
expression was also associated with the metastasis of breast and hepatocellular cancers [16–18], 
suggesting that DLC1 plays an important role not only in tumorigenesis but also in metastasis.  
Focal adhesion kinase (FAK) is an important oncogene that is upregulated in hepatocellular 
carcinoma and breast carcinoma [19,20]. DLC1 can inhibit the metastasis of hepatocellular carcinoma 
by dephosphorylation of FAK [16]. Abnormal expression of DLC1 and p-FAK in many cancers 
suggests that they are involved in the malignant behavior of tumors. p-FAK Y397 contains the major 
site of phosphorylation, tyrosine 397, makes FAK participated in the carcinogenesis of many   
cancers [16,21]. Yet, the roles of DLC1 and p-FAK Y397as well as their potential prognostic values 
remain unknown for EOC. This study was undertaken to evaluate the expression of DLC1 and p-FAK 
Y397 in EOC by immunohistochemistry as well as to explore the roles of DLC1 and p-FAK Y397 in 
the prognosis of advanced stage EOC. 
2. Materials and Methods 
2.1. Patients 
This study was undertaken at the First Affiliated Hospital of Zhengzhou University after approval 
from the Medical Ethical Committee was obtained. For the study, 76 patients who had undergone Int. J. Mol. Sci. 2011, 12                 
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resection of EOC, 20 patients with borderline ovarian tumors and 20 patients with benign ovarian 
tumors were selected during 2000–2005. All of these patients underwent surgery at the Department of 
Gynecology, the First Affiliated Hospital of Zhengzhou University, between May 2000 and December 2005. 
Twenty cases of normal ovarian tissue came from patients with hysteroptosis who had their ovaries 
resected in transvaginal hysterectomy. All of the necessary informed consents were obtained. The 
average patients’ age at the time of surgery was 49 ± 16.6. 
Years old (range: 30–71 years). None of the EOC patients received radio-chemotherapy or 
immunotherapy before surgery. 
2.2. Sample Selection and Grouping 
Paraffin-embedded tissues were obtained from patients with EOC (n = 76), borderline epithelial 
ovarian tumors (n = 20), benign epithelial ovarian tumors (n = 20) and normal ovarian tissue (n = 20). 
Immunohistochemical staining was used to detect the expression of DLC1 and p-FAK Y397. The 
explorative laparotomies, chemotherapies and treatment of patients included in this study were carried 
out at the First Affiliated Hospital of Zhegnzhou University. The mean follow-up was 36 months 
(range: 9–66 months). The patients with EOC stage I/II and in the borderline, benign, and normal 
groups were all alive at the end of follow-up. According to the FIGO 2000 staging standard, patients 
with EOC were classified after surgery as stage I/II (n = 16) and stage III/IV (n = 60). Surgery with 
residual tumor no larger than 1 cm was considered complete. Patients in stage III/IV who received  
6 cycles of postoperative TC (135–175 mg/m
2 paclitaxel and 300–400 mg/m
2 carboplatin after 
calculating the concentration curve) with complete medical records (n = 60) were selected for overall 
survival. Clinicopathologic information was referred from medical records. All cases were diagnosed 
by two pathologists. The stage, grading, histology, age, familial history, malignant effusion and lymph 
metastasis of patients with EOC are summarized in Table 1. 
Table 1. Relationship between the expression of DLC1 and p-FAK Y397 in EOC. 
  p-FAK Y397(−)  p-FAK Y397(+)  χ
2  P 
DLC1(−)  8  38  12.6889  <0.001 
DLC1(+)  17  13     
2.3. Immunohistochemical Staining 
Tissue samples were routinely fixed in 10% buffered formalin, processed and embedded in paraffin. 
Sections were cut at a thickness of 4 μm and dried overnight at 60 C. After deparaffinization, the 
sections were rehydrated in graded dilutions of alcohol and incubated in 0.03% hydrogen peroxide for 
10 min to block endogenous peroxidase. Sections were heated in a microwave oven to 98 C for  
15 min for antigen retrieval and washed in PBS three times. To avoid background staining, the sections 
were then pre-incubated with 5% w/v purified bovine serum albumin (BSA) (Dade Behring, 
Liederbach, Germany) diluted in Tris buffer pH 7.6 for 10 min. The sections were incubated with 
primary antibody overnight at 4 C. The primary specific goat polyclonal antibody against human 
DLC1 (ab21200, Abcam) was diluted 1:50 (38 ng/mL) in 1% w/v purified BSA (Dade Behring) in Tris 
buffer pH 7.6, and the mouse monoclonal antibody against human p-FAK Y397 (sc-1688, Santa Cruz) Int. J. Mol. Sci. 2011, 12                 
 
 
8492
was diluted 1:200 in the same solution. After incubation for 60 min, the sections were then incubated 
with streptavidin-peroxidase conjugate for 30 min at room temperature and washed with PBS   
(3 × 10 min). The color was developed with DAB added with chromogen for 10 min. Sections were 
rinsed in water, counterstained in Mayers Hematoxylin for 3 min and finally dehydrated, mounted  
and coverslipped with Pertex. Washings with 5 mM Tris buffer, pH 7.6 with NaCl 0.9% w/v and 
Tween 0.1% v/v (TBS) were used between all steps in the procedure. After heating, all steps were 
performed at room temperature in a humidity chamber to avoid air-drying of the sections. The positive 
control was a section from breast carcinoma. The negative control staining was done by omitting 
primary antibody. 
Two pathologists who have experience evaluating immunohistochemically stained tissues 
immediately evaluated the expression of DLC1 and p-FAK Y397. A semi-quantitative scoring system 
was used to evaluate the IHC staining. The evaluation of IHC grade was performed by referring to the 
study of Hidemichi W
 [22]. A staining index was obtained from the multiplication of scores of the 
percentage of positive cells (0: <20% positive staining; 1: 20–80%; 2: >80%) and staining intensity  
(0: negative staining; 1: weak; 2: moderate; 3: strong). Scores varying from 0 to 6 were obtained by 
multiplying the two variables. Immunostaining of all slides was evaluated by specialists who were 
blind to the clinical data. Scores of 0–1 were defined as low expression (including negative staining), 
score 2 as moderate expression, and 3 as high expression. The staining of DLC1 and p-FAK Y397 
were divided into negative groups (not stained at all) and positive groups. 
2.4. Statistical Analysis 
The association of expression of DLC1 and p-FAK Y397 in tumor patients was analyzed by 
Contingency Coefficient. Demographics data in DLC1 or p-FAK Y397 were compared using the   
Chi-square test. The expression rates of DLC1 or p-FAK Y397 in four groups were compared by 
logistic regression and Cochran-Armitage trend test. Overall survival was estimated by Kaplan-Meier 
curves. The log-rank test was used to compare the differences between survival curves. The Cox 
regression was used to calculate hazard ratios and 95% confidence intervals (CI). All of the statistical 
analyses were carried out with SAS version 6.12, and two-sided P < 0.05 was considered significant.  
3. Results 
3.1. Relationship Between the Expression of DLC1 and p-FAK Y397 in EOC 
Among the 76 cases of EOC, there were 18 positive for DLC1 and negative for p-FAK Y397 as well as 
41 negative for DLC1 and positive for p-FAK Y397. This result suggests a negative correlation between 
expression of DLC1 and p-FAK Y397 (by Contingency Coefficient r = −0.41, P < 0.001) (Table 1). 
3.2. Expression of DLC1 and p-FAK Y397 in EOC 
The positive immunostaining of DLC1 and p-FAK Y397 appears as cytoplasmic, granular   
brown-colored staining as shown in Figure 1. The frequencies of cytoplasmic expression of DLC1 in 
normal (90%), benign (75%) and borderline tissue (45%) were significantly higher than in EOC 
(39.47%) (P < 0.05, Figure 1A–D, Table 2). There was a decreased trend from the normal group to the Int. J. Mol. Sci. 2011, 12                 
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EOC group (Ztrend = −4.47). However, the expression mode of p-FAK Y397 exhibited an opposite trend. 
The frequencies of cytoplasmic expression of p-FAK Y397 in normal (20%), benign (25%) and borderline 
tissue (55%) were significantly lower than in EOC (67.11%) (P < 0.05, Figure 1E–H, Table 2, Figure 2). 
There was an increased trend from the normal group to the EOC group (Ztrend = −4.50). 
Table 2. DLC1 and p-FAK Y397 expression in various kinds of epithelial ovarian tissues. 
Group 
DLC1 
Positive 
Rate (%) 
OR (95% 
Confidence Interval)
p-FAK Y397 
Positive Rate 
(%) 
OR  
(95% CI) 
DLC1 Negative & 
p-FAK Y397 
Positive n (%) 
OR  
(95% CI)
Normal  18 (90.00)    4 (20.00)    0 (0.00)   
Benign  15 (75.00)  0.333 (0.056–1.971)  5 (25.00)  1.333 (0.300–5.925)  1 (8.33)  - 
Borderline  9 (45.00)  0.091 (0.017–0.501)  11 (55.00)  4.889 (1.199–19.942) 5 (62.50)  - 
Cancer  30 (39.47)  0.072 (0.016–0.335)  51 (67.11)  8.16 (2.469–26.972)  38 (69.09)  - 
Compared to the normal group, the positive expression of DLC1 in the borderline and EOC groups were 
significantly low (Trend test, Z = −4.47, P < 0.001); p-FAK Y397, however, showed a negative trend (Trend 
test, Z = −4.50, P < 0.001); “-”: not computed; n: number. 
Figure 1. (A–D) Deleted in liver cancer 1 × 200 (DLC1) and (E–H) Phosphorylated focal 
adhesion kinase ×200 (p-FAK) Y397 protein expression in various ovarian tissues. Both 
DLC1 and p-FAK Y397 had yellow staining that was mainly localized to the cytoplasm. 
(A) DLC1 positive expression in normal ovarian tissue; (B) DLC1 positive expression in 
benign ovarian tumor; (C) DLC1 positive expression in borderline ovarian tumor;   
(D) DLC1 negative expression in epithelial ovarian carcinoma; (E) p-FAK Y397 negative 
expression in normal ovarian tissue; (F) p-FAK Y397 weak positive expression in benign 
ovarian tumor; (G) p-FAK Y397 positive expression in borderline ovarian tumor;   
(H) p-FAK Y397 positive expression in epithelial ovarian cancer. 
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Figure 2. Bar graph for DLC1 and p-FAK Y397 expression in every group. 
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3.3. Relationship Between DLC1 or p-FAK Y397 Protein Expression and the Clinicopathological 
Parameters in 76 Cases of EOC 
The expression of p-FAK Y397 in patients with lymph metastasis (80.49%) was significantly 
higher than in patients without lymph metastasis (51.43%) (P  = 0.01). The expression of DLC1, 
however, showed no significant difference in lymph metastasis (P = 0.05). The expression of both 
DLC1 and p-FAK Y397 was associated with the stage (χ
2 = 7.27, P < 0.05; χ
2 = 5.01, P < 0.05) and 
ascite (χ
2 = 16.73, P < 0.05; χ
2 = 6.82, P < 0.05). The familial history, age, tumor histology and 
differentiation did not influence the expression of DLC1 and p-FAK Y397 (Tables 3 and 4). 
Table 3. Clinical characteristics and expression of DLC1 and p-FAK Y397 in epithelial 
ovarian carcinoma. 
 
DLC1 (n)  p-FAK Y397 (n) 
(−) (+)  χ
2 P  (−) (+)  χ
2 P 
Age 
≤50 19  13 
0.03 0.86 
10 22 
0.07 0.79 
>50 27  17  15  29 
FIGO stage 
I~II 5  11 
7.27 0.01 
* 
9 7 
5.01 0.03 
* 
III~IV 41  19  16 44 
Lymph metastasis 
N 17  18 
3.88 0.05 
17 18 
7.22 0.01 
* 
Y 29  12  8  33 
Ascites 
N 8  19 
16.73 <0.001 
** 14 13 
6.82 0.01 
* 
Y 38  11  11  38 
Histological differentiation 
poor 14  12 
1.22 0.54 
8 18 
0.99 0.61  moderate 11  8  8  11 
well 21  10  9 22 
Familial history 
Y 44  27 
0.94 0.34 
23 48 
0.12 0.73 
N 2  3  2  3 
* P < 0.05; 
** P < 0.001. Int. J. Mol. Sci. 2011, 12                 
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Table 4. The association between combining of DLC1 and p-FAK Y397 expressions and 
tumor differentiation. 
  Poor  Moderate  Well  χ
2  P 
DLC1(+) & p-FAK Y397(−)  7(41.18)  4(23.53)  6(35.29)  0.7024  0.7038 
DLC1(−) & p-FAK Y397(+)  13(34.21)  7(18.42)  18(47.37)     
3.4. Relationship Between DLC1 and p-FAK Y397 Protein Cytoplasmic Expression, Histological 
Differentiation and the Prognostic Factors of EOC 
Univariate survival analysis demonstrated that histological differentiation, ascites, lymph 
metastasis, as well as expression of DLC1, p-FAK Y397 and DLC1 combined with p-FAK Y397 were 
significant correlative factors with prognosis. However, multivariate Cox analysis showed that only 
histological differentiation (HR = 2.467, 95% CI: 1.126–5.407) and DLC1 combined with p-FAK 
Y397 expression (HR = 3.922, 95% CI: 1.126–13.664) were independent risk factors that influenced 
the prognosis of advanced stage epithelial ovarian cancer (Table 5). In the 60 patients with advanced 
stage EOC, the overall survival of patients with tumors that stained positive for DLC1 and negative for 
p-FAK Y397 significantly differed from that of patients with tumors that stained negative for DLC1 
and positive for p-FAK Y397 (P  < 0.05). The mortality risk of the DLC1-negative and p-FAK   
Y397-positive patients was 3.922 times higher than for DLC1-positive and p-FAK Y397-negative 
patients. (Because the death number of the DLC1-positive and p-FAK Y397-negative patients was  
less than 50%, we used the mortality risk to represent the relationship between the DLC1, p-FAK 
Y397 and the overall survival status). Additionally, Kaplan-Meier survival curves confirmed that 
DLC1-negative and p-FAK Y397-positive patients in advanced stage had decreased overall survival 
time compared to the DLC1-positive and p-FAK Y397-negative patients (Figure 3). Similarly, the 
patients with well-differentiated tumors had a significantly longer overall survival than those with 
poorly differentiated tumors (median survival time 66 months versus 22 months). Patients with 
moderately differentiated tumors showed no difference in overall survival compared with patients who 
had poorly differentiated tumors (median survival time: 19 months and 22 months). Accordingly, 
Kaplan-Meier survival curves indicated that patients with well-differentiated tumors in advanced stage 
had increased overall survival compared to those with moderate and poor differentiation (Figure 4). 
Table 5. Prognostic analysis of 60 cases of epithelial ovarian carcinoma. 
 
Parameter 
Estimation 
Standard 
Error 
χ
2  P Value 
Hazard 
Ratio (HR) 
95% Confidence 
Interval 
Histological differentiation 
moderate vs. well 
0.75737 0.46074 2.7021 0.1002  2.133  0.864  5.261 
Histological differentiation 
poor vs. well 
0.90318 0.40025 5.0919 0.0240  2.467  1.126  5.407 
Lymph metastasis  0.24549  0.41800  0.3449  0.5570  1.278  0.563  2.900 
Ascites 1.07839  0.65236  2.7326  0.0983  2.940  0.819  10.559 
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Table 5. Cont. 
 
Parameter 
Estimation 
Standard 
Error 
χ
2  P Value 
Hazard 
Ratio (HR) 
95% Confidence 
Interval 
DLC1 0.20422  0.53087  0.1480  0.7005  1.227  0.433  3.472 
p-FAK Y397  1.02819  0.59392  2.9971  0.0834  2.796  0.873  8.955 
DLC1 combined with  
p-FAK Y397 
1.36657 0.63686 4.6045 0.0319  3.922  1.126  13.664 
Figure 3. Kaplan-Meier cumulative survival curves showing the association between 
combining of DLC1 and p-FAK Y397 expression and overall survival. 
 
Figure 4. Kaplan-Meier cumulative survival curves showing the association between tumor 
grade of EOC and overall survival. 
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4. Discussion 
DLC1 was recently identified due to its deletion in primary hepatocellular carcinoma and was 
mapped to 8p21.3–22, which is a reported site of tumor suppressor genes [9–13]. The gene structure of 
DLC1 consists of three main parts: sterile alpha motif (SAM), steroidogenic acute regulatory related 
lipid transfer domains (START) and Rho GTPase activating protein (RhoGAP). It is RhoGAP that 
makes DLC1 act as GTPase-activating protein (GAP). Rho family GTPases play important roles in the 
regulation of a variety of cellular processes including cell cycle progression, gene expression, cytoskeletal 
organization, cell morphology, cell migration, and cell adhesion to extra-cellular matrix [14]. DLC1 
participates in the regulation of cytoskeletal rearrangement and morphological changes by inhibiting 
Rho GTPase activity [15]. For several kinds of cancers, DLC1 down-regulation or deletion was 
reported to leave the Rho/ROCK/MLC pathway and RhoA GTPase pathway more active [23,24], 
resulting in the cancer cells’ endless proliferation and migration. 
In the present study, we found that the cytoplasmic expression of DLC1 protein was significantly 
decreased or absent in EOC when compared with other types of ovarian tumor tissues and normal 
ovarian tissues. Previous studies have assessed the expression of DLC1 mRNA in EOC [25]. 
According to Dietmar’s RT-PCR data, DLC1 mRNA was significantly down-regulated in EOC [25], 
but the abnormal expression of DLC1 mRNA was not related to the clinicopathological parameters of 
EOC. The present study, however, indicated that the decreased expression of DLC1 protein was   
related with the FIGO stage and malignant effusions. Based on Dietmar’s study, our data suggest that 
post-transcriptional control of DLC1 might affect the development of EOC. Metastasis is a direct 
factor in the recurrence of many cancers and an immediate index of prognosis of cancers [26–28]. 
Micrometastatic lesions and circulating tumor cells [29,30] might contribute to the relapse of the 
cancer. Therefore, metastasis-related genes play a key role in predicting the prognosis of cancer.   
In breast cancer, DLC1 was shown to be down-regulated by thrombospondin2 (TSP2) and was 
implicated as a contributor to the micrometastasis of breast cancer [21]. In a study by Zhang et al., 
expression of DLC1 was intimately correlated with the metastasis and prognosis of clear cell renal cell 
carcinoma [31]. In concordance with these studies, our data indicate that deactivation of DLC1 was an 
importment molecular changement in EOC. 
FAK is a non-receptor tyrosine kinase. As such, FAK can be activated at tyr397 by many protein 
tyrosine kinases such as PI3K and Grb7 and subsequently regulate focal adhesion dynamics during  
cell migration and activate prosurvival and mitogenic signaling pathways [20,21]. Published studies 
have reported high expression of p-FAK in cancers like hepatocellular carcinoma [19] and breast 
carcinoma [20]. Our data indicate that the cytoplasmic expression of p-FAK Y397 was higher in EOC 
than other types of ovarian tissues. Moreover, its high expression was closely related to the FIGO 
stage, malignant effusions and metastastic lymph nodes of EOC. Consistent with the study in breast 
carcinoma [20], the results of this study suggest that the phosphorylation of FAK might be another 
molecular changement closely related with EOC. 
The difference of correlation with lymph metastasis between DLC1 and p-FAK Y397 might be due 
to p-FAK’s central involvement in many signaling pathways. The complex integration of many 
pathways might contribute to p-FAK’s involvement in the lymph metastasis of EOC. By acting on 
various downstream molecules, DLC1 controls cell growth and migration in different kinds of   Int. J. Mol. Sci. 2011, 12                 
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cancers [16,32–34]. As one of the downstream genes of DLC1, FAK can be dephosphorylated on 
tyr397 and tyr925; the subsequently down-regulated p-FAK Y397 and p-FAK Y925 are able to play 
important roles in tumor suppression and metastasis suppression [16]. It is worth noting that we have 
discovered an obvious negative correlation between the expression of DLC1 and p-FAK Y397 in 
EOC: lower expression of DLC1 was associated with higher expression of p-FAK Y397 in EOC. This 
result indicates that abnormal DLC1 expression might contribute to EOC by altering the expression of 
p-FAK Y397. Kim et al. found that after transfection of DLC1 in hepatocellular carcinoma cells, the 
expression of p-FAK, paxillin and p130cas were down-regulated and cell proliferation and migration 
were inhibited [16]. Our results, combined with other studies, indicated that DLC1 and   
p-FAK Y397 might be promising new therapeutic targets for EOC, though their value for this 
application requires further verification. We also found that cytoplasmic expression of DLC1 and   
p-FAK Y397 did not correlate with familial history, suggesting DLC1 and p-FAK Y397 are not factors 
in heredity EOC. 
Differentiation has always been demonstrated as an independent prognostic factor of EOC [35–37]. 
Cho et al. [35] held that the differentiation of EOC determined the cell biology and the subsequent 
response to therapy, making differentiation an independent prognostic factor of EOC not only in stage 
I but also in advanced stage. The data from the present study also support these conclusions.  
Although the univariate analyses indicated that both DLC1 and p-FAK were prognostic factors, on 
multivariate Cox regression analysis they were found to not be independent risk factors for the 
prognosis of EOC in advanced stage. Notably, the combination of DLC1 and p-FAK Y397 was an 
independent risk factor of EOC in advanced stage, and this was confirmed by multivariate Cox 
regression analysis. The overall survival time for the DLC1-negative and p-FAK Y397-positive group 
was short, while that for the DLC1-positive and p-FAK Y397-negative group was relatively long.  
Log-rank test revealed significant differences between the two groups. A similar trend was observed in 
the well-differentiated and moderate- to poorly-differentiated groups. The survival analysis data in the 
present study strengthens the notion that DLC1 contributes to the carcinogenesis and metastasis of 
advanced stage EOC by interacting with FAK. Table 4 shows that there was no association between 
combining of DLC1 and p-FAK Y397 expressions and tumor differentiation (P = 0.7038). On one 
hand, this data just supports the idea that both combining of DLC1 and p-FAK Y397 expressions and 
differentiation was the independent prognosis factor for EOC. On the other hand, this means that the 
alteration of DLC1 and p-FAK Y397 might not be the intrinsic mechanisms for the differentiation of 
EOC. Besides metastasis, chemoresistance can also directly cause relapse and impact the prognosis of 
EOC. Studies have
 found that p-FAK might be involved in the chemoresistance of EOC and other 
cancers [38,39]. The significant prognostic value of p-FAK Y397 also hints that therapy response 
might be another way that p-FAK directly correlates with the prognosis of advanced stage EOC, 
though this requires further confirmation. It seems that in this pilot study, histological differentiation 
remains a more accurate independent prognostic factor (P = 0.0240) than DLC1 and p-FAK (P = 0.0319). 
The presented data showed that DLC1 combined with p-FAK Y397 was an independent risk factor 
of advanced stage EOC as well as histological differentiation. Targeting either DLC1 or p-FAK Y397 
might be a potential strategy for controlling the metastasis of EOC. Int. J. Mol. Sci. 2011, 12                 
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